German CDMO Vetter has confirmed its plans to build a production facility in the Saarland region of southwest Germany.
Construction is scheduled to begin in the second quarter of 2026. Initially, approximately €480m has been allocated for the first construction phase of the new commercial production plant. Operations are expected to commence in 2031.
The company acquired the approximately 95-acre industrial property in the city of Saarlouis at the end of 2024. Vetter sees the potential to create up to 2,000 jobs in the long term. The European Commission has approved up to €47m of state aid for the project.
“With the construction of our new production facility in Germany, we continue on our path to sustainable growth. Long-term success derives from striking the right balance between stability and expansion,” said Senator h.c. Udo J. Vetter, chairman of the Advisory Board and member of the owner family.
“With our investments in the state of Saarland, only a five-hour drive away from our headquarters in Ravensburg, we are strengthening our commitment to Germany’s economic landscape while reaffirming our engagement as a strategic partner to the global pharmaceutical market.”
The company recently began construction on a new clinical production site in Des Plaines, Illinois, US.
To meet growing customer demand and increasing market requirements, the company is investing in its existing sites in Germany, Austria, and the US. With its newly planned commercial site, Vetter will significantly expand its production capacity.